Saturday 17 October 2026
Export CORT’s income statement to Excel — free account
Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
110.16
3.21
−2.83%
Follow CORT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
105.44 | 16.05 | 20.55 | 14.58 | 28.43 | 22.76 | 21.23 | 23.46 | 37.33 | 37.02 |
Piotroski F-Score |
8 | 6 | 6 | 6 | 6 | 7 | 8 | 6 | 6 | 4 |
Altman Z-Score |
13.37 | 42.41 | 27.82 | 22.52 | 39.90 | 31.75 | 18.86 | 20.51 | 22.11 | 14.11 |
P/S ratio |
10.01 | 12.94 | 6.13 | 4.51 | 8.53 | 6.26 | 5.36 | 5.19 | 7.71 | 4.75 |
P/FCF ratio |
44.72 | 34.03 | 13.36 | 10.25 | 20.03 | 13.68 | 17.96 | 19.78 | 26.52 | 25.49 |
Altman Z″-Score (non-manufacturers) |
(9.04) | 8.35 | 13.02 | 15.38 | 18.28 | 15.09 | 14.21 | 11.64 | 10.22 | 8.97 |
Beneish M-Score |
(2.48) | 4.42 | (3.23) | (2.76) | (2.65) | (2.69) | (2.83) | (2.14) | (2.26) | (2.76) |
P/Operating CF |
178.11 | 82.76 | 71.61 | 28.56 | 86.09 | 46.33 | 64.51 | 452.52 | 86.61 | 94.01 |
P/B ratio |
19.67 | 10.78 | 5.59 | 3.73 | 5.77 | 6.09 | 4.29 | 4.94 | 7.65 | 5.58 |
Price to Tangible BV |
19.67 | 10.78 | 5.59 | 3.73 | 5.77 | 6.09 | 4.29 | 4.94 | 7.65 | 5.58 |
EV/Sales |
9.60 | 12.47 | 5.37 | 3.65 | 7.32 | 5.68 | 4.31 | 4.45 | 7.16 | 4.28 |
EV/EBITDA |
75.89 | 37.46 | 15.32 | 9.84 | 19.85 | 15.61 | 14.75 | 21.33 | 37.96 | 78.33 |
EV/Operating CF |
42.45 | 32.57 | 11.66 | 8.23 | 17.04 | 12.37 | 14.40 | 16.93 | 24.38 | 22.94 |
EV/FCF |
42.90 | 32.79 | 11.69 | 8.29 | 17.18 | 12.41 | 14.45 | 16.95 | 24.65 | 22.97 |
Quick Ratio |
2.24 | 3.95 | 6.31 | 7.62 | 9.83 | 5.28 | 6.38 | 3.92 | 3.11 | 2.60 |
Current Ratio |
2.40 | 4.20 | 6.66 | 7.91 | 10.08 | 5.60 | 6.89 | 4.39 | 3.35 | 2.92 |
Net Debt/EBITDA |
(3.58) | (1.68) | (2.35) | (2.41) | (3.37) | (1.68) | (3.67) | (3.66) | (2.96) | (8.83) |
Debt/Assets |
21.33% | 0.00% | 0.00% | 0.46% | 0.09% | 0.00% | 0.00% | 0.00% | 0.73% | 0.60% |
Debt/Equity |
0.35 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Asset Turnover |
1.35 | 1.10 | 0.94 | 0.85 | 0.72 | 0.74 | 0.80 | 0.80 | 0.92 | 0.91 |
Operating CF/Net income |
2.26 | 0.47 | 1.53 | 1.45 | 1.43 | 1.49 | 1.19 | 1.20 | 1.42 | 1.45 |
Capex/Depreciation |
(1.80) | (3.49) | 0.20 | (0.50) | (0.55) | (0.05) | (0.09) | 0.02 | 0.23 | 0.07 |
| 27.19% | 111.15% | 32.31% | 29.11% | 23.70% | 25.03% | 23.08% | 20.92% | 23.56% | 14.79% | |
| 13.49% | 89.27% | 28.34% | 26.02% | 21.55% | 22.60% | 20.11% | 17.51% | 19.11% | 11.71% | |
ROIC |
141.16% | 32.32% | 80.92% | 71.82% | 96.37% | 51.09% | 100.32% | 48.42% | 28.31% | 9.98% |
Return on Tangible Assets |
21.13% | 135.73% | 37.35% | 34.94% | 24.50% | 51.16% | 23.70% | 29.77% | 41.90% | 30.56% |
Average Days of Receivables |
44.26 | 64.64 | 25.55 | 23.73 | 27.02 | 27.55 | 28.21 | 31.12 | 29.19 | 28.66 |
Research and Development Expense of Revenue |
29.32% | 25.36% | 29.95% | 29.04% | 32.43% | 31.11% | 32.60% | 38.22% | 36.57% | 33.48% |
Selling, General and Administrative Expense of Revenue |
55.63% | 39.21% | 32.35% | 32.75% | 29.76% | 33.43% | 38.04% | 38.20% | 41.53% | 58.93% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
8.68% | 8.39% | 9.45% | 9.56% | 9.48% | 11.73% | 10.56% | 10.15% | 9.09% | 11.10% |
Graham Net Nets |
0.05 | 0.05 | 0.13 | 0.19 | 0.14 | 0.10 | 0.19 | 0.14 | 0.06 | 0.08 |
Graham Number |
0.77 | 6.54 | 5.91 | 7.79 | 9.69 | 7.98 | 10.02 | 10.65 | 14.14 | 11.49 |
Earnings Yield |
0.95% | 6.23% | 4.87% | 6.86% | 3.52% | 4.39% | 4.71% | 4.26% | 2.68% | 2.70% |
Free Cash Flow Yield |
2.24% | 2.94% | 7.49% | 9.76% | 4.99% | 7.31% | 5.57% | 5.06% | 3.77% | 3.92% |
Revenue per Share |
0.74 | 1.40 | 2.18 | 2.68 | 3.07 | 3.16 | 3.76 | 4.66 | 6.54 | 7.33 |
Operating CF per Share |
0.17 | 0.54 | 1.00 | 1.19 | 1.32 | 1.45 | 1.13 | 1.22 | 1.92 | 1.37 |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 |
Free Cash Flow per Share |
0.16 | 0.53 | 1.00 | 1.18 | 1.31 | 1.45 | 1.12 | 1.22 | 1.90 | 1.37 |
Cash per Share |
0.47 | 0.78 | 1.79 | 2.41 | 3.82 | 1.93 | 4.04 | 3.56 | 3.71 | 3.58 |
Shareholders Equity per Share |
0.37 | 1.68 | 2.39 | 3.25 | 4.53 | 3.25 | 4.70 | 4.89 | 6.58 | 6.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.37 | 1.68 | 2.39 | 3.25 | 4.53 | 3.25 | 4.70 | 4.89 | 6.58 | 6.24 |
Free Cash Flow |
18.20 | 60.52 | 115.37 | 135.03 | 150.73 | 167.42 | 119.91 | 126.54 | 196.12 | 141.79 |
Working Capital |
38.32 | 94.62 | 201.25 | 268.52 | 431.01 | 218.92 | 426.76 | 354.13 | 330.83 | 319.38 |
Capital Expenditures |
(0.19) | (0.42) | (0.30) | (1.09) | (1.24) | (0.47) | (0.41) | (0.14) | (2.17) | (0.21) |
Net Current Asset Value |
38.32 | 94.62 | 201.01 | 266.23 | 430.11 | 218.51 | 417.67 | 343.82 | 310.64 | 296.62 |
EV/EBIT |
76.69 | 37.55 | 15.06 | 10.03 | 20.20 | 16.69 | 15.39 | 19.99 | 35.30 | 72.71 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
79.95 | 38.96 | 17.22 | 12.40 | 23.55 | 18.40 | 19.12 | 23.32 | 37.98 | 80.68 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.53 | 0.23 | (2.27) | 2.07 | 1.34 | 8.54 | 7.63 | (34.70) | (3.57) | (1.70) |
Cash ROIC |
16.92% | 21.64% | 23.90% | 20.80% | 15.63% | 27.93% | 12.85% | 14.46% | 18.35% | 13.83% |
Accounts Receivable Turnover |
10.11 | 8.37 | 10.98 | 16.34 | 15.34 | 13.60 | 13.70 | 13.37 | 14.20 | 13.39 |
Accounts Payable Turnover |
1.14 | 0.65 | 0.62 | 0.70 | 0.62 | 0.60 | 0.57 | 0.44 | 0.66 | 0.47 |
Inventory Turnover |
1.03 | 1.03 | 1.12 | 1.08 | 1.08 | 1.07 | 0.97 | 0.94 | 1.08 | 1.03 |
Average Days of Payables |
406.15 | 881.07 | 578.54 | 499.82 | 690.11 | 477.45 | 811.74 | 979.72 | 515.74 | 1,137.56 |
Days of Inventory on Hand |
413.06 | 469.96 | 331.19 | 359.69 | 321.06 | 344.75 | 413.46 | 435.34 | 416.32 | 361.93 |
Average Receivables |
8.04 | 19.03 | 22.89 | 18.76 | 23.06 | 26.91 | 29.34 | 36.09 | 47.55 | 56.88 |
Average Payables |
1.81 | 5.43 | 8.42 | 7.90 | 9.05 | 8.73 | 9.44 | 14.69 | 16.39 | 27.91 |
Average Inventory |
2.01 | 3.45 | 4.65 | 5.08 | 5.17 | 4.95 | 5.54 | 6.92 | 10.07 | 12.64 |
Average Assets |
60.33 | 144.65 | 266.12 | 362.00 | 492.02 | 497.74 | 503.59 | 602.47 | 731.04 | 838.60 |
Average Common Equity |
29.94 | 116.17 | 233.43 | 323.53 | 447.26 | 449.57 | 438.82 | 504.27 | 593.15 | 663.70 |
Columns are period end dates